Stryker Co. (NYSE:SYK) Shares Sold by USS Investment Management Ltd

USS Investment Management Ltd lowered its position in Stryker Co. (NYSE:SYK - Free Report) by 6.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,431 shares of the medical technology company's stock after selling 4,162 shares during the quarter. USS Investment Management Ltd's holdings in Stryker were worth $23,201,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Capital & Planning LLC boosted its stake in shares of Stryker by 3.6% during the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock valued at $304,000 after buying an additional 29 shares during the last quarter. Merit Financial Group LLC lifted its position in shares of Stryker by 20.9% during the fourth quarter. Merit Financial Group LLC now owns 8,862 shares of the medical technology company's stock worth $3,191,000 after purchasing an additional 1,535 shares during the last quarter. HB Wealth Management LLC raised its stake in Stryker by 2.4% during the fourth quarter. HB Wealth Management LLC now owns 9,476 shares of the medical technology company's stock valued at $3,412,000 after buying an additional 221 shares in the last quarter. Grove Bank & Trust lifted its holdings in Stryker by 43.4% during the 4th quarter. Grove Bank & Trust now owns 175 shares of the medical technology company's stock worth $63,000 after buying an additional 53 shares during the last quarter. Finally, Annex Advisory Services LLC grew its position in shares of Stryker by 63.0% in the 4th quarter. Annex Advisory Services LLC now owns 13,549 shares of the medical technology company's stock worth $4,878,000 after acquiring an additional 5,235 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

NYSE SYK opened at $394.63 on Tuesday. The stock has a market cap of $150.63 billion, a P/E ratio of 50.85, a PEG ratio of 2.93 and a beta of 0.93. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company's 50-day simple moving average is $367.24 and its 200 day simple moving average is $375.80.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter last year, the company earned $2.50 EPS. Stryker's revenue was up 11.9% on a year-over-year basis. As a group, research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio is currently 45.41%.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on SYK. Sanford C. Bernstein set a $450.00 price objective on shares of Stryker in a report on Monday, May 5th. Needham & Company LLC reiterated a "buy" rating and set a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. The Goldman Sachs Group set a $422.00 target price on Stryker in a report on Tuesday, March 4th. Royal Bank of Canada boosted their price objective on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $427.05.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.